Canary Medical has completed the first-in-human clinical trial of its Cardiac Auscultation monitoring sensor device.

The new implantable sensor is aimed at enhancing the management of congestive heart failure symptoms.

Conducted in Paraguay, the limited feasibility trial has demonstrated the device's potential in providing daily objective cardiac parameter measurements.

This enables clinicians and patients to better manage their symptoms with medication management tools that are currently available.

The limited feasibility trial focused on evaluating the sensitivity, specificity, and design specifications of the microphone system of the device.

Two patients were part of this trial, which confirmed the sensor's ability to detect mitral regurgitation sound signals, distinguishing them from normal acoustic heart signals.

Canary Medical founding member and CEO Bill Hunter said: “Today, Canary Medical announced the first step in expanding our sensor technology applications outside of orthopedics. The Cardiac Auscultation monitor is just one of the exciting new products that will drive the future growth of our company.

“Congratulations to our world-class research and development team and thank you to the individuals who were the first to receive this new technology. While these are early results, we believe that the future is bright for patients who will benefit from Canary’s expanded sensor portfolio in the years to come.”

In the US, heart failure market is expected to reach $70bn annually by 2030.

In 2022, Canary Medical launched Canary Quantiles Recovery Curves, its first orthopaedic analytic module.

The new Canary Quantiles Recovery Curves software is designed to provide additional aggregate population data to healthcare professionals while managing a patient’s total knee arthroplasty after surgery.